Free Biopharma Daily Stock Updates - 03/23/22
$XBI $89.86 | -2.55% Covid Updates $MRNA -4.3% Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 ...
top of page
BPIQ Blog
Mar 22, 20222 min read
Free Biopharma Daily Stock Updates - 03/22/22
$XBI $92.21 | +3.58% Covid Updates $NVAX +6.7% Novavax and Serum Institute of India Announce First Emergency Use Authorization of...
Mar 21, 20222 min read
Free Biopharma Daily Stock Updates - 03/21/22
$XBI $89.02 | -3.41% Covid Updates $MRNA -2.0% Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven...
Mar 18, 20222 min read
Biopharma Pulse - 3/14 - 3/18 Week in Review
As we reach the middle of March, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves...
Mar 18, 20221 min read
Free Biopharma Daily Stock Updates - 03/18/22
$XBI $92.16 | +2.9% Covid Updates $MRNA +6.3% MODERNA SUBMITS AMENDMENT TO THE EMERGENCY USE AUTHORIZATION FOR AN ADDITIONAL BOOSTER...
Mar 17, 20221 min read
Free Biopharma Daily Stock Updates - 03/17/22
$XBI $89.56| +3.91% Covid Updates $MRNA -0.5% Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years) source $EIGR...
Mar 16, 20221 min read
Free Biopharma Daily Stock Updates - 03/16/22
$XBI $86.19 | +4.79% Covid Updates $ Pipeline Updates $AZN +1.0% Lynparza reduced risk of death by 32% in the adjuvant treatment of...
Mar 15, 20221 min read
Free Biopharma Daily Stock Updates - 03/15/22
$XBI $82.26 | +1.47% Covid Updates $PFE 0.0% Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster...
Mar 14, 20222 min read
Free Biopharma Daily Stock Updates - 03/14/22
$XBI $81.07 | -4.18% Covid Updates $ADMP -6.1% Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the...
Mar 11, 20223 min read
Smid-cap Biopharmas Trading Near Cash
(Originally posted 3/11/22) (Updated 3/13/22) 2022 has been a challenging year thus far for biotech investors with XBI down 27% YTD and...
Mar 11, 20221 min read
Biopharma Pulse - 3/7 - 3/11 Week in Review
As we enter March, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD...
Mar 11, 20221 min read
Free Biopharma Daily Stock Updates - 03/11/22
$XBI $84.53 | -3.9% Pipeline Updates $HARP -27.4% Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and...
Mar 10, 20221 min read
Free Biopharma Daily Stock Updates - 03/10/22
$XBI $87.98 | -0.5% Covid Updates $MRNA -2.1% Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent...
Mar 10, 20222 min read
GTHX - Bull Thesis
BULL THESIS GTHX overall corporate and summary Commercial-stage cancer biopharma company focused on the development and commercialization...
Mar 10, 20222 min read
MDGL - Bull Thesis
BULL THESIS MDGL overall corporate and executive summary Pursuing novel therapeutics that target a specific thyroid hormone pathway in...
Mar 9, 20221 min read
Free Biopharma Daily Stock Updates - 03/09/22
$XBI $88.44 | +4.89% Covid Updates $ Pipeline Updates $NTLA +3.7% Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for...
Mar 8, 20222 min read
Free Biopharma Daily Stock Updates - 03/08/22
$XBI $84.32 | +0.67% Covid Updates Pipeline Updates $AFMD +1.5% Affimed Announces Clinical Updates at the Annual Meeting of the American...
Mar 7, 20222 min read
Free Biopharma Daily Stock Updates - 03/07/22
$XBI $83.76 | -0.17% Covid Updates Pipeline Updates $LVTX +1.4% LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO...
Mar 4, 20221 min read
HGEN - Bull Thesis
BULL THESIS HGEN overall corporate and executive summary Multiple upcoming Phase 3 trials for 2022 Lenzi appears to be an active and safe...
Mar 4, 20221 min read
Biopharma Pulse - 2/28-3/4 Week in Review
As we have reached the end of February, we review moves from smid-cap biopharma companies during this past week as well as for the month...
Jump start your biotech due diligence
Our platform helps you uncover your next biotech investment opportunity
bottom of page